Drug Profile

JW 0061

Alternative Names: CWL-080061; CWL-08061; JW-0061

Latest Information Update: 12 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator JW Pharmaceutical
Class Skin disorder therapies; Small molecules
Mechanism of Action Glial cell line-derived neurotrophic factor receptor agonists; Wnt signalling pathway stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

13 Apr 2026 Phase-I clinical trials in Alopecia (In volunteers) in South Korea (unspecified route) (NCT07514780)
07 Apr 2026 JW Pharmaceutical plans a phase I trial for Alopecia (In volunteers) in South Korea (NCT07514780)
07 Oct 2024 JW 0061 is still in preclinical development for Alopecia in South Korea (JW Pharmaceutical pipeline, October 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com